Thermo Fisher Launches Automated Cell Therapy Manufacturing System

Thermo Fisher Scientific has unveiled the Gibco CTS Compleo Fill and Finish System, a cutting-edge technology designed to revolutionize cell therapy manufacturing. The system, launched globally, brings automation and a functionally closed solution to streamline the formulation and filling processes, thus minimizing risks and ensuring consistency.

The announcement marks a significant milestone in cell therapy production, addressing challenges like variability and contamination often associated with manual handling. As the leader in scientific services, Thermo Fisher recognizes the need for automated solutions in a landscape where cell therapies, derived from patient cells, are becoming more common. The new system promises to reduce manual interventions, maintain sterility, support dose accuracy, and ensure consistent product quality. With the potential for wide integration into existing workflows, the system is poised to facilitate the commercialization of therapies by enhancing operational efficiency. Industry collaborators, such as Arsenal Biosciences, are already witnessing the benefits of this innovation, which offers seamless integration and flexibility across various programs.

Thermo Fisher’s launch of the Gibco CTS Compleo system signifies a leap forward in cell therapy manufacturing, offering a streamlined, scalable solution that could transform how life-changing therapies are delivered to patients. By enhancing process consistency and reducing variability, the system not only addresses critical manufacturing bottlenecks but also supports the broader goal of bringing advanced therapies to market more efficiently.